

DEC 01 2005


PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/821734	
	Filing Date	03/30/2001	
	First Named Inventor	Pedyczak, Artur	
	Group Art Unit	1642	
	Examiner Name	Sheela Jitendra Huff	
Total Number of Pages in This Submission	7	Attorney Docket Number	API-02-07-US

ENCLOSURES <i>(check all that apply)</i>		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i> <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>
Remarks Transmitted via facsimile to 571-273-8300		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Patrick J. Halloran
Signature	
Date	12/01/2005

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 			
Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
CENTRAL FAX CENTER

DEC 01 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Docket No. API-02-07-US)

In re Application of:)	
)	
Pedyczak, et al.)	
)	
Serial No.: 09/821,734)	Examiner: S.J. Huff
)	
Filing Date: March 30, 2001)	Art Unit: 1642
)	
For: IMMUNOGENIC PEPTIDES DERIVED)	
FROM PROSTATE-SPECIFIC)	
MEMBRANE ANTIGEN (PMSA) AND)	
USES THEREOF)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted via facsimile to 703-872-9306

RESPONSE TO OFFICE ACTION DATED SEPTEMBER 1, 2005

Dear Sir / Madam,

This is a response to the Office Action dated September 1, 2005. A fax transmittal form is attached to this response. Applicants do not believe any petitions or fees are due with this response. In the event any additional petitions are due, Applicants hereby make such petitions. With respect to fees, the undersigned hereby authorizes the Commissioner to deduct any additional fees or credit any overpayment to Deposit Account No. 50-0244.

Amendments to the Claims begin on page 2 of this submission.

Remarks / Conclusions begin at page 4 of this submission.